BOCA RATON, Fla., July 10, 2018 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), and CellMark Medical, a global supply chain service company, today announced a new partnership to support and accelerate international growth and encourage worldwide adoption of Sensus’ groundbreaking technologies for oncological and aesthetic indications.
“CellMark Medical was formed to create a pathway for domestically successful, innovative medical technologies to expand from their home markets into emerging geographic locations around the world,” said Oliver Moorhouse, Head of the Americas, CellMark Medical. “As the preference is to focus on underserved clinical areas, such as skin cancer and keloids, we view Sensus Healthcare as a partner for life, and the opportunity to expedite and sustain this global growth is truly a privilege. Achieving inaugural solution commitments in international markets within six months of launching speaks volumes for the collaboration that we have developed with the Sensus management team.”
The collaboration aims to facilitate timely access for patients all over the world to Sensus’ extensive portfolio of aesthetic and dermatology solutions, including SRT and Sensus Laser Systems, as well as the Company’s future oncology solutions. CellMark Medical will leverage its proprietary trading platform and healthcare industry networks to develop sales and distribution channels in global markets, as well as work with new and existing sales partners to facilitate effective cross-border supply chain operations.
Following Sensus’ distribution deals earlier this year in China, Mexico and Thailand, among others, Sensus Healthcare and CellMark Medical will now focus on expanding distribution to Japan, Southeast Asia, Central and South America and Canada. The partnership has already led to the successful order of the first SRT-100 solution in Vietnam by Dr. Vu Quang Vinh, Head of the Department of Plastic and Aesthetic Reconstructive Surgery at the National Hospital of Burns in Ha Noi.
“Sensus’ collaboration with CellMark Medical offers a critical boost of support to Sensus’ international business development, which is a key priority for the Company this year,” added Rick Golin, Sensus Healthcare Executive Vice President of International Sales. “Combining Sensus’ expertise in aesthetic and dermatological solutions with CellMark Medical’s product shipping, warehousing, financing, market-specific experience and worldwide user / distributor digital CMDS system enables wider, more efficient global reach, ultimately helping to bring Sensus’ transformative technology to more patients in need all over the world.”
About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids. Sensus uses a proprietary low-energy X-ray technology known as superficial radiotherapy (SRT), which is a result of over a decade of dedicated research and development. Sensus has successfully incorporated SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit https://www.sensushealthcare.com.
Forward-Looking Statements
This press release includes statements that are, or may be deemed, ‘forward-looking statements.’ In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words.
By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare, regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements contained in this press release, as a result of, among other factors: our ability to achieve and sustain profitability; market acceptance of the SRT-100 product line; our ability to successfully commercialize our products, including the SRT-100; our ability to compete effectively in selling our products and services, including responding to technological change and cost containment efforts of our customers; our need and ability to obtain additional financing in the future, as well as complying with the restrictions our existing revolving credit facility imposes; our ability to expand, manage and maintain our direct sales and marketing organizations; our actual financial results may vary significantly from forecasts and from period to period; our ability to successfully develop new products, improve or enhance existing products or acquire complementary products, technologies, services or businesses; our ability to obtain and maintain intellectual property of sufficient scope to adequately protect our products, including the SRT-100, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; market risks regarding consolidation in the healthcare industry; the willingness of healthcare providers to purchase our products if coverage, reimbursement and pricing from third party payors for procedures using our products significantly declines; the level and availability of government and third party payor reimbursement for clinical procedures using our products; our ability to effectively manage our anticipated growth, including hiring and retaining qualified personnel; the regulatory requirements applicable to us and our competitors; our ability to manufacture our products to meet demand; our reliance on third party manufacturers and sole- or single-source suppliers; our ability to reduce the per unit manufacturing cost of the SRT-100; our ability to efficiently manage our manufacturing processes; the regulatory and legal risks, and certain operating risks, that our international operations subject us to; off label use of our products; the fact that product quality issues or product defects may harm our business; the accuracy of our financial statements and accounting estimates, including allowances for accounts receivable and inventory obsolescence; any product liability claims; limited trading in our shares and the concentration of ownership of our shares; cyberattacks and other data breaches and the adverse effect on our reputation; new legislation, administrative rules, or executive orders, including those that impact taxes and international trade regulation; the provisions in our certificate of incorporation, bylaws, or Delaware law that discourage takeovers or that limit certain disputes to be brought exclusively in the Delaware Court of Chancery; geographic concentration of our customers in the U.S. and China; and other risks described from time to time in Sensus Healthcare’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016.
In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release. You should read carefully our “Cautionary Note Regarding Forward-Looking Information” and the factors described in the “Risk Factors” section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.
Media Contacts for Sensus:
Caitlin Kasunich / Kathryne Hunter
KCSA Strategic Communications
212-896-1241 / 212-896-1204
ckasunich@kcsa.com / khunter@kcsa.com
Investor Contact for Sensus:
Kim Sutton Golodetz
LHA Investor Relations
(212) 838-3777
kgolodetz@lhai.com
About CellMark
Headquartered in Gothenburg, Sweden, CellMark leverages an expert global trading infrastructure, with a network across 120 markets, to simplify the exporting process and minimize associated risks. This allows MedTech manufacturers transparent control of their international sales operations through a well-established distribution partner. CellMark coordinates the regulatory approval process in the local market where needed, ensuring that necessary documents are comprehensively vetted and delivered to the correct authorities in a timely manner, and leveraging an in-depth network of experts to quickly overcome any local obstacles. More information can be found here: http://www.cellmark.com/divisions-business-units/medical.
View original content:http://www.prnewswire.com/news-releases/sensus-healthcare-and-cellmark-medical-partner-to-accelerate-international-expansion-and-growth-for-innovative-oncology-and-aesthetic-solutions-300677866.html
SOURCE Sensus Healthcare